ArticleInternational journal of colorectal disease2005
Gene expression profiles of different clinical stages of colorectal carcinoma: toward a molecular genetic understanding of tumor progression.
Article in International journal of colorectal disease, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 63 citations in OpenAlex.
- Primary Colorectal Tumor Displays Differential Genomic Expression Profiles Associated with Hepatic and Peritoneal Metastases.Cancers · 2023Article
- New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy.Seminars in cancer biology · 2023Review
- Investigation of the expression levels of CPEB4, APC, TRIP13, EIF2S3, EIF4A1, IFNg, PIK3CA and CTNNB1 genes in different stage colorectal tumorsTurkish journal of medical sciences · 2021Article
- L-serine synthesis via the phosphorylated pathway in humans.Cellular and molecular life sciences : CMLS · 2020Review
- The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with an increased tumour mutational burden.Scientific reports · 2020Article
- Positive expression of basic transcription factor 3 predicts poor survival of colorectal cancer patients: possible mechanisms involved.Cell death & disease · 2019Article
- Identification of genes and pathways, including the CXCL2 axis, altered by DNA methylation in hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2019Article
- Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer.BMC cancer · 2018Article
- Article
- Interferon-inducible CXC-chemokines are crucial immune modulators and survival predictors in colorectal cancer.Oncotarget · 2017Article
- Gene-expression analysis of a colorectal cancer-specific discriminatory transcript set on formalin-fixed, paraffin-embedded (FFPE) tissue samples.Diagnostic pathology · 2015Article
- Identification of differential proteins in colorectal cancer cells treated with caffeic acid phenethyl ester.World journal of gastroenterology · 2014Article
- Bifidobacterium bifidum PRL2010 modulates the host innate immune response.Applied and environmental microbiology · 2014Article
- Clinical applications of gene expression in colorectal cancer.Journal of gastrointestinal oncology · 2013Article
- Prediction of metastasis and recurrence in colorectal cancer based on gene expression analysis: ready for the clinic?Cancers · 2011Article
- Comparative profiling of primary colorectal carcinomas and liver metastases identifies LEF1 as a prognostic biomarker.PloS one · 2011Article
- Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas.Genes, chromosomes & cancer · 2010Article
- Article
- Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival.International journal of colorectal disease · 2010Article
- Genomic markers for decision making: what is preventing us from using markers?Nature reviews. Clinical oncology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsColorectal cancer is one of the leading causes of cancer deaths in the Western world. A better understanding of the development and progression of colorectal carcinoma is needed to define novel targets and strategies for treatment. PATIENTS/
methodsGene expression profiles were determined for primary tumors of 10 locally restricted (T3N0M0), 8 lymphatically metastasized (T3N+M0), 7 systemically metastasized (T3N+M1) colorectal carcinomas, and 6 specimens of normal colorectal tissue by histology-guided oligonucleotide microarray analysis.
resultsA total of 1,995 genes were differently regulated in primary tumors of colorectal carcinoma compared with normal colorectal tissue. Besides common features of dedifferentiation and different expression of genes involved in cell division, cell adhesion, angiogenesis, signal transduction and metabolism we observed a deregulation of genes with an as yet unclear function. We identified 126 genes that were subsequently up- and 204 genes down-regulated during tumor progression. Furthermore, we found a cluster of five genes exclusively up-regulated in primary tumors of systemically metastasized colorectal carcinomas. A comparison of locally restricted (T3N0M0) and systemically metastasized (T3N+M1) primary tumors showed 50 deregulated genes with a massive down-regulation of immune-modulatory genes in primary tumors of systemically metastasized carcinomas. Primary tumors of lymphatically (T3N+M0) and systemically metastasized (T3N+M1) carcinomas differed in the expression of 19 genes.
conclusionThese results provide an additional step toward the identification of crucial genes for the progression of colorectal cancer and the identification of novel treatment targets or strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.